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SUMMARY
Current antiseizure therapy is ineffective in approximately one third of people with
epilepsy and is often associated with substantial side effects. In addition, most current
therapeutic paradigms offer treatment, but not cure, and no therapies are able to
modify the underlying disease, that is, can prevent or halt the process of epileptogene-
sis or alleviate the cognitive and psychiatric comorbidities. Preclinical research in the
field of epilepsy has been extensive, but unfortunately, not all the animal models being
used have been validated for their predictive value. The overall goal of TASK2 of the
AES/ILAE Translational Task Force is to organize and coordinate systematic reviews
on selected topics regarding animal research in epilepsy. Herein we describe our strat-
egy. In the first part of the paper we provide an overview of the usefulness of system-
atic reviews and meta-analysis for preclinical research and explain the essentials for
their conduct. Then we describe in detail the protocol for a first systematic review,
which will focus on the identification and characterization of outcome measures
reported in animal models of epilepsy. The specific goals of this study are to define
systematically the phenotypic characteristics of the most commonly used animal
models, and to effectively compare these with the manifestations of human epilepsy.
This will provide epilepsy researchers with detailed information on the strengths and
weaknesses of epilepsy models, facilitating their refinement and future research.
Ultimately, this could lead to a refined use of relevant models for understanding the
mechanism(s) of the epilepsies and developing novel therapies.
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HARMONIZATION INPRECLINICAL EPILEPSYRESEARCH
Introduction: Systematic
Reviews and Meta-Analyses
Historically, the medium of scientific communication
limited the access of researchers to data. Now the opposite
holds: the Internet and electronic citation repositories allow
access to huge amounts of data that in most circumstances
cannot be assimilated by a single individual. Because each
scientist must be extremely selective in their reading, there
is a high risk of acquisition bias. Moreover, the statistical
power of single studies in basic and preclinical research is
often insufficient to draw solid conclusions, which may
therefore be either falsely positive or negative. False nega-
tives mean potentially valuable lines of research are shut
down prematurely, whereas false positives inflate our
appreciation of the effect size.1,2 Widespread publication
bias can also lead to a false impression of the potential value
of an area of research.3 This is especially so because posi-
tive results are more likely to be published in high impact
journals and high impact journals are, by definition, more
likely to be cited.
These problems have been addressed in clinical research
by means of systematic reviews of the literature and meta-
analysis of the data (Fig. 1). Systematic reviews provide a
scientific approach to the collection, grading, and interpre-
tation of large volumes of data. Detailing the search strategy
used to explore the literature and defining inclusion and
exclusion criteria allows readers to judge for themselves
whether the writers have taken a rigorous approach to find-
ing relevant data, providing a critical element of science: a
defined methodology that allows others to confirm and
extend the results. Meta-analysis allows aggregating and re-
analyzing of the data from systematic reviews. This can pro-
vide greater statistical power, leading to the discovery of
effects that were not evident within single data sets, and can
lessen the risk of chance associations (false positives).
In basic and preclinical research, the breadth of available
data and heterogeneity of study design necessitate a
different approach to the systematic review and meta-analy-
sis process employed in clinical science. Assessments of
risk of bias and estimation of the effect size for a single
intervention can still be made, but the heterogeneity of
design also facilitates study of the methodologies employed
to model disease and of the underlying biologic variables
that influence outcome.4–10
Conduct of Systematic Reviews
and Meta-Analyses on Animal
Research
Protocol
The prospective registration of protocols is recognized as
an important part of the conduct of systematic reviews in the
clinical sciences. Establishing a protocol for the research we
intend to conduct serves a number of important functions
that reduce waste and minimize the risk of biases. If proto-
cols are registered in an open database, potential authors can
Figure 1.
The process of systematic reviews and meta-analyses. White cir-
cles represent individual papers containing different sets of data
(circles, squares, hexagons, stars). Data that are relevant for the
study (represented as blue squares) are extracted and combined in
a meta-analysis.
Epilepsia ILAE
Key Points
• Systematic reviews provide a scientific approach to
the collection, grading, and interpretation of
large volumes of data
• A goal of the AES/ILAE Translational Task Force is to
organize and coordinate systematic reviews regarding
animal research in epilepsy
• The first systematic review will focus on the character-
ization of outcome measures reported in animal mod-
els of epilepsy
• This article describes in detail the protocol for this sys-
tematic review
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determine if another group has already initiated a systematic
review on the same topic and decide whether to proceed
with their review. Prospective registration also minimizes
the potential for publication bias by maintaining a perma-
nent record of initiated reviews, regardless of publication
status. Finally, by describing a priori the analyses to be
performed, a protocol protects against “HARKing”
(Hypothesizing After Results are Known).
PROSPERO (http://www.crd.york.ac.uk/PROSPERO/)
is an international prospective registry for systematic review
protocols in human health. Expanding PROSPERO’s scope
to include systematic reviews of preclinical studies will
provide authors with a central source for registering and
searching for protocols. In addition to such registration, it is
appropriate for protocols to be published in peer-reviewed
journals to provide more details on the background/rationale
and methods.
Search strategy
A comprehensive search strategy is essential to identify
all studies relevant to a particular topic. The first steps in
designing a comprehensive search strategy are the follow-
ing: (1) translating the review questions into clear and sim-
ple ones, (2) defining search components, and (3) building
comprehensive search strategies that identify intersections
of search components. SYRCLE (https://www.radboud
umc.nl/Research/Organisationofresearch/Departments/cdl/
SYRCLE/Pages/default.aspx) has developed several tools
to specifically facilitate the search process for animal-based
studies.11–13
One of the greatest challenges in designing a comprehen-
sive search is to find the right balance between sensitivity
and specificity. Sensitivity is the proportion of relevant arti-
cles identified by a search strategy as a percentage of all rel-
evant articles on a given topic. It is a measure of the ability
of a search strategy to identify all relevant articles. Speci-
ficity is the proportion of relevant articles identified by a
search strategy as a percentage of all articles (relevant and
irrelevant) identified by that search. In other words, it is a
measure of the ability of a search strategy to exclude irrele-
vant articles. Searches with a high sensitivity often result in
relatively low specificity and vice versa. To increase sensi-
tivity of the search, the Cochrane handbook for systematic
reviews of interventions14 suggests using multiple databases
in a search. However, although clinical researchers have
begun to grapple with the issues of coverage of different
databases,15–18 little is known about the effect of search
strategy, and database selection in particular, on the validity
of systematic reviews in the context of animal studies.19
Approaches to statistical analysis
Different approaches can be used to pool data from indi-
vidual studies and provide summary estimates of effect.
Although the fundamental principles are the same as for
meta-analyses of human clinical trial data, some important
differences should be considered in animal research. Clini-
cal research reviews are usually based on a small number of
studies involving large cohorts of patients, investigating a
homogenous treatment effect. In contrast, animal research
reviews often involve a large number of studies, each with a
small number of cases and, in general, with substantial
heterogeneity in the circumstances of testing (species, dose,
timing of treatment, outcome assessed). Although the pur-
pose of clinical meta-analyses is usually to produce a better
estimate of the treatment effect, such an estimate (e.g.,
improvement of drug outcome in a particular disease)
generally has little meaning in animal studies. Rather, what
is important are the associations between different aspects
of experimental design and the observed effects, which
might define the limits to efficacy; circumstances in which
efficacy is not observed; the prevalence and impact of publi-
cation bias; and the impact of reporting of other risks of bias.
Such an approach helps to define the reaction norms of the
biologic response.
Effect size may be represented as the following: (1) a
mean difference (i.e., all outcomes use the same scale); (2) a
standardized mean difference (i.e., the effect is scaled
according to the observed variance); or (3) a normalized
mean difference (i.e., the effect is scaled as a proportionate
improvement in outcome). Because animal studies rarely
use the same scale and because the observed variance is an
imprecise measure of the population variance, a normalized
mean difference (NMD) approach is often used. When this
is not possible, analyses based on standardized mean differ-
ence (SMD) can be used, but have lower statistical power
because of the measurement error in the estimation of effect
sizes.
Sources of heterogeneity between different studies may
be assessed through partitioning of the observed hetero-
geneity (i.e., the weighted sum of the squared deviations
from the fixed effects estimate) into that occurring within
groups and that occurring between groups. Alternatively,
meta-regression seeks to build a univariate or multivariate
regression equation, which minimizes the weighted-squared
deviations from the model. Although both approaches have
strengths, modeling suggests that partitioning of hetero-
geneity is much less conservative, in statistical terms, than
meta-regression (http://www.dcn.ed.ac.uk/camarades/files/
CAMARADES%20Monograph%201.pdf).
In this project we will use the partitioning of heterogene-
ity to summarize SMD effect sizes and meta-regression
when NMD effect sizes are used.
Publication standards andmeta-bias
As with any type of research, systematic reviews and
meta-analyses are susceptible to bias. It was found in a
systematic review of systematic reviews of preclinical
studies that 30% specified a testable hypothesis, 27% per-
formed a literature search without language restrictions,
17% assessed for the presence of publication bias, 50%
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assessed study validity, and 2% investigated sources of
heterogeneity.20 It is only through clear reporting of what
was done that it is possible to assess the risk of bias. The
potential users of the systematic reviews need to be able
to assess whether the methodologies are sound and inter-
pretations are valid.
Protocol for a Systematic
Review on Animal Research in
Epilepsy
There are many different topics of interest in preclinical
epilepsy research, which are worthy subjects for systematic
reviews and meta-analysis. As a start, our working group
agreed that it would be relevant to identify and characterize
the outcome measures that are the most frequently used to
evaluate outcome in animal models of epilepsy. These are
among the most important “tools of our trade” and it is criti-
cal to how they behave in different models of our disease
and to understand which are fit for the task. This broad anal-
ysis will provide the foundations for more sharply focused
reviews. Once we know which of our assessment tools are
effective, we can more effectively probe the relevance of
our broad range of epilepsy and seizure models and the rela-
tive merits of individual corrective drugs.
Below, we provide a detailed protocol of this initial work,
which has already been registered in the CAMARADES
website (http://www.dcn.ed.ac.uk/camarades/files/epilepsy
%20models%20protocol%20final.pdf).
Background
Epilepsy is one of the most common neurologic dis-
eases. It affects an estimated 1% of the population, that is,
>50 million individuals worldwide. Approximately one in
25 people will develop epilepsy at some point in their
lifetime and it is estimated that 2.4 million people are
newly diagnosed with epilepsy each year (http://
www.who.int/mediacentre/factsheets/fs999/en/).21 In addi-
tion, neurologic and psychiatric comorbidities contribute
heavily to the disability of this population of patients.
Since the introduction of the bromides as an antiseizure
drug almost two centuries ago, many effective therapies
have been tested and introduced in clinical practice. These
treatments have been referred to as “antiepileptic drugs”
(AEDs), and about 20 of them have been developed dur-
ing the past 30 years. However, all AEDs are symp-
tomatic agents that, at best, control the most obvious
manifestation of the disease, that is, seizures. For this rea-
son, the term “antiseizure drugs” (ASDs) is now pre-
ferred.22 However, seizures are still not adequately
controlled in a third of the cases, ASDs often have side
effects, and no disease-modifying therapies (which
remove the susceptibility to seizures) are yet available.
Moreover, there are no therapies that specifically address
the comorbidities of epilepsy. Therefore, an urgent
demand exists to address these unmet clinical needs.23,24
Preclinical research in epilepsy has strongly facilitated
the discovery of ASDs with different mechanisms of action.
Traditionally, these new therapies have been identified
based on effects in preventing chemically (pentylenetetra-
zol, PTZ) or electrically (maximal electroshock, MES)
induced acute seizures in otherwise normal animals or, more
recently, in slowing kindling progression or increasing sei-
zure threshold in fully kindled animals. These tests have
been performed by individual research teams, by compa-
nies, or by the Epilepsy Therapy Screening Program (previ-
ously named the Anticonvulsant Screening Program, ASP),
an initiative of the National Institute for Neurological Dis-
eases and Stroke (NINDS). Some of the new ASDs intro-
duced to the clinic as a result of this approach proved more
tolerable, but the percentage of patients with drug-resistant
epilepsy has not changed, and these new drugs have not
proved effective in preventing epilepsy development in at-
risk individuals or in treating comorbidities.25 Probably
because testing for tolerability and safety has been done in
acute (and not chronic) epilepsy models, current screening
methods have often failed to elucidate which drugs will pro-
duce significant adverse effects. Additional models (such as
6 Hz and status epilepticus models) have been proposed as
additions to the screening, but these have not yet been fully
validated for their predictiveness of therapeutic effects in
human disease.24 In addition, the similarities of their charac-
teristics with the human symptoms (i.e., their face validity)
have been questioned.26,27
In summary, despite its important achievements, epilepsy
therapy development still needs to address major existing
unmet clinical gaps. To meet these demands, redesign of
current translational approaches is needed. The aims of this
systematic review are to define the phenotypic features of
some commonly used models, in order to effectively com-
pare these to the aspects of the human clinical condition
they are intended to model. This will provide epilepsy
researchers with detailed information of the most commonly
used models for future research and ideas on how the exist-
ing models could be improved. Ultimately, this could lead
to a refined use of relevant models for understanding the
mechanism(s) of the epilepsies and identifying novel thera-
pies. To achieve these goals, (1) we created a list of animal
models of induced epilepsy (Table 1) based on a report of
the United Kingdom’s National Centre for Replacement,
Refinement and Reduction of Animals in Research
(NC3Rs) epilepsy working group28 and on a preliminary
screening of the literature run by the authors; the list will be
further refined following a more detailed screening to iden-
tify how many articles are published per model and select a
more limited group of representative models to examine in
detail; and (2) we identified relevant outcome measures that
would allow ascertainment of the impact of therapeutic
interventions (Table 2).
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Objectives of the systematic review andmeta-analysis
As described earlier, animal studies have been instrumen-
tal in the identification of new effective ASDs. The species
that proved most useful in this respect were small rodents
(mice and rats), but much valuable data have also been
obtained in other species ranging from fish (zebrafish) to
primates. In this study, we will collect and examine results
obtained in mammalian species. Non-mammalian species
will be excluded only because the phenotypical presentation
of the disease in these species is far less complex than in
humans, preventing an in-depth comparison.
Acquired epilepsies in humans are often caused by an
initial epileptogenic insult (head trauma, episode of status
epilepticus, stroke, brain infection, hyperthermia) that, after
a latency period, may lead to the occurrence of spontaneous
seizures and the diagnosis of epilepsy. All these epilepto-
genic insults can be reproduced in animals and, as in
humans, may lead to spontaneous seizures after a latency
period. Therefore, in this study we will consider all inter-
ventions intended by the authors to evoke acquired epilepsy.
Interventions intended to induce a single seizure only will
not be included. Because this is not a therapeutic interven-
tion, we will use the term “epileptogenic insult.” Data from
animals not receiving the epileptogenic insult (sham ani-
mals or animals receiving vehicle rather than epileptogenic
drug or insult) will serve as the control population. We will
categorize all reported outcomes as electrophysiologic
(electroencephalography, EEG), behavioral, histologic, or
imaging. Detailed analysis will focus on specific outcome
measures selected on the basis of a survey among preclinical
and clinical epilepsy experts (Table 2). The definitions and
classifications of seizures are currently being developed by
TASK1 of the AES/ILAE Translational Task Force, and are
reported in detail in other articles of this supplement.
Specifically, our research questions are the following: (1)
What outcome measures are commonly reported in animal
experiments modeling epilepsy? (2) To what extent do the
changes associated with model induction reflect human epi-
lepsy (face validity)? (3) What is the statistical performance
(power to detect a given effect size) of different outcome
measures, and does this differ between models?
The protocol below describes the methodology we plan
to use to pursue an answer to these questions.
Methods
Search strategy
Databases to search. Based on previous experience, we
chose to search PubMed and Embase databases.
Electronic search strategies. We will run the following
search: [animal study string12,13] AND [all chronic models
(named one by one)] AND [epilepsy]. The animal study
strings are reported in the Appendix.
Study selection procedures
Screening phases. PubMed and Embase search results
will be downloaded to EndNote, and full text of articles
retrieved when available using the automated EndNote fea-
ture (not available articles will be obtained via interlibrary
loan or direct contact with authors). Unique results will be
exported from Endnote as an XML file and uploaded into
the SyRF application (http://app.syrf.org.uk/). Screening for
inclusion/exclusion of titles and abstracts will be performed
against the criteria below. Publications passing stage 1 will
proceed to stage 2 according to the criteria. The SyRF appli-
cation allows that each screener is offered each record only
once; and records are offered for screening until two review-
ers agree on disposal (inclusion or exclusion).
Table 1. Models of induced epilepsy
Electrical Chemical Physical
Electrically induced status epilepticus
(amygdala stimulation, perforant
path stimulation)
Pilocarpine
Lithium-pilocarpine
Traumatic brain injury (fluid percussion, controlled
cortical impact)
Penetrating brain injury
Kindling (corneal, hippocampal,
amygdaloidal, pentylenetetrazol)
Kainic acid (intra-amygdala, intrahippocampal,
intracerebroventricular, intraperitoneal,
subcutaneous)
Hypoxia
Hypoxic-ischemic encephalopathy
HyperthermiaTetanus toxin
Osmotic blood–brain barrier disruptionBicuculline intrahippocampal
StrokePenicillin cortical
AlbuminFerric salts (intra-amygdala or intraneocortex)
Prenatal teratogen, maternal stress and teratogen model
of autism and epilepsy
Cobalt cortical
Neurocysticercosis
Viral encephalitis (Theiler’s murine encephalomyelitis
virus model)
Multiple hit model of infantile spasms
Tetrodotoxin model of spasm
Undercut
Epilepsia, 58(Suppl. 4):68–77, 2017
doi: 10.1111/epi.13908
72
M. Simonato et al.
Table 2. Outcomemeasures
Outcome Scale Measure
EEG
Percent of tested animals with seizures Ordinal Quantitative measure: %
Frequency of spontaneous seizures Ordinal Quantitative measure: seizures/day
Duration of spontaneous seizures Ordinal Quantitative measure: sec
Cumulative duration of seizure per EEG session (time
spent seizing)
Ordinal Quantitative measure: sec
Frequency of interictal spikes Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
High frequency oscillations Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Seizure threshold Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Seizure spread Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Behavior—seizures
Percent of tested animals with seizures Ordinal Quantitative measure: %
Semiology of seizures (different types) Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Frequency of convulsive seizures Ordinal Quantitative measure: seizures/day
Duration of convulsive seizures Ordinal Quantitative measure: sec
Severity of convulsive seizures Nominal Quantitative measure: Racine scale (specify the Racine scale variant
employed in the study)
Postictal behavior (e.g., postictal depression or
alterations in behavior following seizures)
Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Seizure threshold Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Behavior—comorbidities
Anxiety- and depression-associated behavior
Open field Ordinal Quantitative measure: entries in the central quadrants (number/
min).
Elevated plus maze Ordinal Quantitative measure: entries in the open arms (number/min).
T maze Ordinal Quantitative measure: number of correct choices (% correct).
Forced swimming Ordinal Quantitative measure: immobility (% total time of observation).
Light/dark (black/white) box Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Glucose preference Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Weight change Ordinal Quantitative measure: weight gain per week
Cognitive impairment
Novel object recognition Ordinal Quantitative measure: % time exploring novel object.
Morris water maze Ordinal Quantitative measure: % time in target quadrant in the probe trial.
Barnes Maze Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Nesting behavior Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Autism
Ultrasonic vocalization (USV) Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Social exploration/interaction Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Repetitive behavior Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Sleep impairment
Sleep EEG Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Histologic
Cell death
Hippocampal volume Ordinal Quantitative measure: % control volume.
Cell counting Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Neuronal loss Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Fluoro-Jade Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
TUNEL Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Neurogenesis
BrDU, Ki67, etc. Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Gliosis
GFAP Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Microgliosis
Iba1, Cd11b Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Neuroinflammation
Cytokines, cyclooxygenase-2, . . . Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Alterations in organization and morphology
Granule cell dispersion Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Continued
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Study selection criteria
Inclusion and exclusion criteria. Inclusion: controlled
studies comparing outcomes between a group of animals in
which the epileptogenic insult has been induced and a group
of animals not receiving that epileptogenic insult. Exclu-
sion: acute seizure models; studies on transgenic and knock-
out mice; drug efficacy studies where outcomes are
compared only in cohorts that have received an intervention
intended to model epilepsy (no nonepileptic control); publi-
cations that do not contain primary data (i.e., review arti-
cles).
Type of intervention.Any epileptogenic insult intended to
induce a model of epilepsy (i.e., chronically reduced seizure
threshold or induce spontaneous recurrent seizures or both).
Language restrictions.Only articles in English.
Publication date restrictions.None.
Exclusion criteria per selection phase. Stage 1. This will
be a screening phase based only on title and abstract. Inclu-
sion criteria: (1) papers written in English; (2) concerning
the induced epilepsy models listed in Table 1; (3) using
mammalian species. Exclusion criteria: (1) paper not writ-
ten in English; (2) not concerning the induced epilepsy
models listed in Table 2; (3) using non-mammalian species.
Stage 2. This will be the extraction phase, in which infor-
mation will be extracted from the full text. The outcome
measure and the mode of information extraction are listed in
Table 2 and below (“Study characteristics to be extracted”).
The reason for an extensive list of outcomes in Table 2 is
proposed to reduce a priori preconceptions of what out-
comes are important, and we will employ statistical methods
to account for multiplicity of comparisons.
Study characteristics to be extracted
All study characteristics will be extracted by two inde-
pendent reviewers with discrepancies resolved by a third
reviewer.
Study ID.Unique study identifiers will be generated auto-
matically for each article and will be linked to the basic
information of the publication extracted from the online
searching engines.
Study design characteristics (e.g., experimental groups,
number of animals). Number of animals per experiment and
per experimental cohort.
Animal model characteristics. For each experiment, and
for each experimental cohort:
1. Species, strain, and, where available, breeder;
2. Gender;
3. Age (or weight as a surrogate if age is not given);
4. Housing (singly- vs. group-housed).
Intervention characteristics. For each experiment, and
for each experimental cohort:
1. Method of induction of epilepsy;
2. Timing, and, when appropriate, number and intensity of
induction events (i.e., drug dose, electrical stimulation
parameters, amount of infective agent, etc.).
Outcome measures. For each experiment:
1. Category of outcome measure (see Table 2);
2. Timing(s) of outcome assessment.
For each experimental cohort:
1. Median or mean outcome at each time point;
2. Variance or interquartile range (IQR) of mean or median
outcome.
Assessment risk of bias (internal validity) or study quality
Number of reviewers assessing the risk of bias/study
quality in each study and resolution of discrepancies. Two
reviewers will be assigned to assess the risk of bias and
study quality. Discrepancies will be resolved by a third
screener.
Criteria to assess the internal validity of included studies
and/or other study quality measures. The study quality
checklist described by CAMARADES29 study will be
adapted as follows:
• Publication in peer-reviewed journal;
• Random allocation to group;
• Blinded conduct of the experiment;
• Blinded assessment of outcome;
• Sample size calculation;
• Reporting of animals excluded from analysis and reasons
for exclusion (e.g., health status, general conditions, or
other parameters);
• Reported health status and general condition;
• Monitoring duration longer than 1 week (for adult animal
models);
• Continuous (vs. discontinuous) monitoring (for adult ani-
mal models);
Table 2. Continued.
Outcome Scale Measure
Sprouting of the mossy fibers (Timm, ZnT3,
dynorphin)
Alterations in dendritic arborization Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Blood–brain barrier integrity
Albumin, IgG, or other means to assess integrity of
the blood–brain barrier
Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Imaging
Magnetic resonance imaging Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
Positron emission tomography Dichotomous Qualitative measure: yes/no (just note if evaluated in the paper)
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• Video-EEGmonitoring;
• Information about the course of spontaneous recurrent
seizures (i.e., progression/regression/remission).
Collection of outcome data
Type of data to be extracted for each outcome measure.
See Table 2.
Methods for data extraction/retrieval.Multi-modal:
1. From text;
2. From graphs using a digital ruler software.
Data analysis and synthesis
How will data be combined/compared.Meta-analysis.
How it will be decided whether a meta-analysis will be
performed. Meta-analysis will be performed where >10
experimental comparisons are available.
Effect measure. For dichotomous outcomes we will pre-
sent odds ratios. For continuous outcomes we will use stan-
dardized mean difference.
Statistical model of analysis. Random effects meta-analy-
sis.
Statistical methods to assess heterogeneity. I2 and Q.
Which study characteristics will be examined as potential
source of heterogeneity (subgroup analysis). Species; age at
intervention; gender; housing (single vs. group; enrich-
ment); time to outcome assessment; randomization, blind-
ing.
Sensitivity analyses.Meta-regression.
Other meta-analysis details. To adjust for multiple test-
ing of study design (n = 4) and risk of bias (n = 5) items we
will use a Bonferroni-Holm correction.
Method to assess for risk of publication bias. Risk of pub-
lication bias analyses will be assessed using funnel plot
assessment and Egger’s regression. Trim and fill analysis
will be used to assess the potential impact of publication
bias.
Concluding Remarks
As stated, we expect that the protocol outlined in this arti-
cle will lead to a series of systematic reviews and meta-ana-
lyses on preclinical epilepsy research. Once we have
completed the analysis on the general features of the models
and of their similarities to the human epilepsy condition, the
following obvious step will be to analyze the effects of the
Food and Drug Administration (FDA)- and European
Medicines Agency (EMA)-approved drugs using the same
approach.
This study is expected to provide concrete evidence to
inform attempts to improve the currently available models
of chronic epilepsy and the conduct of preclinical epilepsy
research. In addition, we believe that this will help provid-
ing a more realistic and translationally usable view of the
data generated by preclinical epilepsy research, identifying
areas that need further exploration and providing more solid
bases for the initiation and design of clinical studies.
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Appendix
Animal Study Search String for
PubMed12
(“animal experimentation”[MeSH Terms] OR “models, animal”[MeSH
Terms] OR “invertebrates”[MeSH Terms] OR “Animals”[Mesh:noexp]
OR “animal population groups”[MeSH Terms] OR “chordata”[MeSH
Terms:noexp] OR “chordata, nonvertebrate”[MeSH Terms] OR “verte-
brates”[MeSH Terms:noexp] OR “amphibians”[MeSH Terms] OR “bird-
s”[MeSH Terms] OR “fishes”[MeSH Terms] OR “reptiles”[MeSH Terms]
OR “mammals”[MeSH Terms:noexp] OR “primates”[MeSH Terms:no-
exp] OR “artiodactyla”[MeSH Terms] OR “carnivora”[MeSH Terms] OR
“cetacea”[MeSH Terms] OR “chiroptera”[MeSH Terms] OR “ele-
phants”[MeSH Terms] OR “hyraxes”[MeSH Terms] OR “insec-
tivora”[MeSH Terms] OR “lagomorpha”[MeSH Terms] OR
“marsupialia”[MeSH Terms] OR “monotremata”[MeSH Terms] OR
“perissodactyla”[MeSH Terms] OR “rodentia”[MeSH Terms] OR “scan-
dentia”[MeSH Terms] OR “sirenia”[MeSH Terms] OR “xenarthra”[MeSH
Terms] OR “haplorhini”[MeSH Terms:noexp] OR “strepsirhini”[MeSH
Terms] OR “platyrrhini”[MeSH Terms] OR “tarsii”[MeSH Terms] OR
“catarrhini”[MeSH Terms:noexp] OR “cercopithecidae”[MeSH Terms]
OR “hylobatidae”[MeSH Terms] OR “hominidae”[MeSH Terms:noexp]
OR “gorilla gorilla”[MeSH Terms] OR “pan paniscus”[MeSH Terms] OR
“pan troglodytes”[MeSH Terms] OR “pongo pygmaeus”[MeSH Terms])
OR ((animals[tiab] OR animal[tiab] OR mice[Tiab] OR mus[Tiab] OR
mouse[Tiab] OR murine[Tiab] OR woodmouse[tiab] OR rats[Tiab] OR rat
[Tiab] OR murinae[Tiab] OR muridae[Tiab] OR cottonrat[tiab] OR cotton-
rats[tiab] OR hamster[tiab] OR hamsters[tiab] OR cricetinae[tiab] OR
rodentia[Tiab] OR rodent[Tiab] OR rodents[Tiab] OR pigs[Tiab] OR pig
[Tiab] OR swine[tiab] OR swines[tiab] OR piglets[tiab] OR piglet[tiab]
OR boar[tiab] OR boars[tiab] OR “sus scrofa”[tiab] OR ferrets[tiab] OR
ferret[tiab] OR polecat[tiab] OR polecats[tiab] OR “mustela putorius”[tiab]
OR “guinea pigs”[Tiab] OR “guinea pig”[Tiab] OR cavia[Tiab] OR cal-
lithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] OR cebuella[Tiab]
OR hapale[Tiab] OR octodon[Tiab] OR chinchilla[Tiab] OR chinchillas
[Tiab] OR gerbillinae[Tiab] OR gerbil[Tiab] OR gerbils[Tiab] OR jird
[Tiab] OR jirds[Tiab] OR merione[Tiab] OR meriones[Tiab] OR rabbits
[Tiab] OR rabbit[Tiab] OR hares[Tiab] OR hare[Tiab] OR diptera[Tiab]
OR flies[Tiab] OR fly[Tiab] OR dipteral[Tiab] OR drosophila[Tiab] OR
drosophilidae[Tiab] OR cats[Tiab] OR cat[Tiab] OR carus[Tiab] OR felis
[Tiab] OR nematoda[Tiab] OR nematode[Tiab] OR nematodes[Tiab] OR
sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] OR canine[Tiab] OR cani-
nes[Tiab] OR canis[Tiab] OR sheep[Tiab] OR sheeps[Tiab] OR mouflon
[Tiab] OR mouflons[Tiab] OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab]
OR capra[Tiab] OR capras[Tiab] OR rupicapra[Tiab] OR rupicapras[Tiab]
OR chamois[Tiab] OR haplorhini[Tiab] OR monkey[Tiab] OR monkeys
[Tiab] OR anthropoidea[Tiab] OR anthropoids[Tiab] OR saguinus[Tiab]
OR tamarin[Tiab] OR tamarins[Tiab] OR leontopithecus[Tiab] OR homi-
nidae[Tiab] OR ape[Tiab] OR apes[Tiab] OR “pan paniscus”[Tiab] OR
bonobo[Tiab] OR bonobos[Tiab] OR “pan troglodytes”[Tiab] OR gibbon
[Tiab] OR gibbons[Tiab] OR siamang[Tiab] OR siamangs[Tiab] OR
nomascus[Tiab] OR symphalangus[Tiab] OR chimpanzee[Tiab] OR chim-
panzees[Tiab] OR prosimian[Tiab] OR prosimians[Tiab] OR “bush
baby”[Tiab] OR bush babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR
pongidae[Tiab] OR gorilla[Tiab] OR gorillas[Tiab] OR “pongo pyg-
maeus”[Tiab] OR orangutan[Tiab] OR orangutans[Tiab] OR lemur[Tiab]
OR lemurs[Tiab] OR lemuridae[Tiab] OR horse[Tiab] OR horses[Tiab]
OR equus[Tiab] OR cow[Tiab] OR calf[Tiab] OR bull[Tiab] OR chicken
[Tiab] OR chickens[Tiab] OR gallus[Tiab] OR quail[Tiab] OR bird[Tiab]
OR birds[Tiab] OR quails[Tiab] OR poultry[Tiab] OR poultries[Tiab] OR
fowl[Tiab] OR fowls[Tiab] OR reptile[Tiab] OR reptilia[Tiab] OR reptiles
[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab]
OR alligator[Tiab] OR alligators[Tiab] OR crocodile[Tiab] OR crocodiles
[Tiab] OR turtle[Tiab] OR turtles[Tiab] OR amphibian[Tiab] OR amphib-
ians[Tiab] OR amphibia[Tiab] OR frog[Tiab] OR frogs[Tiab] OR bombina
[Tiab] OR salientia[Tiab] OR toad[Tiab] OR toads[Tiab] OR “epidalea
calamita”[Tiab] OR salamander[Tiab] OR salamanders[Tiab] OR eel[Tiab]
OR eels[Tiab] OR fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR catfish
[Tiab] OR catfishes[Tiab] OR siluriformes[Tiab] OR arius[Tiab] OR
heteropneustes[Tiab] OR sheatfish[Tiab] OR perch[Tiab] OR perches
[Tiab] OR percidae[Tiab] OR perca[Tiab] OR trout[Tiab] OR trouts[Tiab]
OR char[Tiab] OR chars[Tiab] OR salvelinus[Tiab] OR minnow[Tiab] OR
cyprinidae[Tiab] OR carps[Tiab] OR carp[Tiab] OR zebrafish[Tiab] OR
zebrafishes[Tiab] OR goldfish[Tiab] OR goldfishes[Tiab] OR guppy[Tiab]
OR guppies[Tiab] OR chub[Tiab] OR chubs[Tiab] OR tinca[Tiab] OR bar-
bels[Tiab] OR barbus[Tiab] OR pimephales[Tiab] OR promelas[Tiab] OR
“poecilia reticulata”[Tiab] OR mullet[Tiab] OR mullets[Tiab] OR eel
[Tiab] OR eels[Tiab] OR seahorse[Tiab] OR seahorses[Tiab] OR mugil
curema[Tiab] OR atlantic cod[Tiab] OR shark[Tiab] OR sharks[Tiab] OR
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catshark[Tiab] OR anguilla[Tiab] OR salmonid[Tiab] OR salmonids[Tiab]
OR whitefish[Tiab] OR whitefishes[Tiab] OR salmon[Tiab] OR salmons
[Tiab] OR sole[Tiab] OR solea[Tiab] OR lamprey[Tiab] OR lampreys
[Tiab] OR pumpkinseed[Tiab] OR sunfish[Tiab] OR sunfishes[Tiab] OR
tilapia[Tiab] OR tilapias[Tiab] OR turbot[Tiab] OR turbots[Tiab] OR flat-
fish[Tiab] OR flatfishes[Tiab] OR sciuridae[Tiab] OR squirrel[Tiab] OR
squirrels[Tiab] OR chipmunk[Tiab] OR chipmunks[Tiab] OR suslik[Tiab]
OR susliks[Tiab] OR vole[Tiab] OR voles[Tiab] OR lemming[Tiab] OR
lemmings[Tiab] OR muskrat[Tiab] OR muskrats[Tiab] OR lemmus[Tiab]
OR otter[Tiab] OR otters[Tiab] OR marten[Tiab] OR martens[Tiab] OR
martes[Tiab] OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR
ermine[Tiab] OR mink[Tiab] OR minks[Tiab] OR sable[Tiab] OR sables
[Tiab] OR gulo[Tiab] OR gulos[Tiab] OR wolverine[Tiab] OR wolverines
[Tiab] OR mustela[Tiab] OR llama[Tiab] OR llamas[Tiab] OR alpaca
[Tiab] OR alpacas[Tiab] OR camelid[Tiab] OR camelids[Tiab] OR gua-
naco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] OR chiropteras[Tiab]
OR bat[Tiab] OR bats[Tiab] OR fox[Tiab] OR foxes[Tiab] OR iguana
[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] OR parakeet[Tiab] OR
parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR
donkeys[Tiab] OR mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras
[Tiab] OR shrew[Tiab] OR shrews[Tiab] OR bison[Tiab] OR bisons[Tiab]
OR buffalo[Tiab] OR buffaloes[Tiab] OR deer[Tiab] OR deers[Tiab] OR
bear[Tiab] OR bears[Tiab] OR panda[Tiab] OR pandas[Tiab] OR “wild
hog”[Tiab] OR “wild boar”[Tiab] OR fitchew[Tiab] OR fitch[Tiab] OR
beaver[Tiab] OR beavers[Tiab] OR jerboa[Tiab] OR jerboas[Tiab] OR
capybara[Tiab] OR capybaras[Tiab]) NOTmedline[sb]).
Animal Study Search String for
Embase13
exp animal experiment/or exp animal model/or exp experimental ani-
mal/or exp transgenic animal/or exp male animal/or exp female animal/or
exp juvenile animal/OR animal/OR chordata/OR vertebrate/OR tetrapod/
OR exp fish/OR amniote/OR exp amphibia/OR mammal/OR exp reptile/
OR exp sauropsid/OR therian/OR exp monotremate/OR placental mam-
mals/OR exp marsupial/OR Euarchontoglires/OR exp Afrotheria/OR exp
Boreoeutheria/OR exp Laurasiatheria/OR exp Xenarthra/OR primate/OR
exp Dermoptera/OR exp Glires/OR exp Scandentia/OR Haplorhini/OR exp
prosimian/OR simian/OR exp tarsiiform/OR Catarrhini/OR exp Platyr-
rhini/OR ape/OR exp Cercopithecidae/OR hominid/OR exp hylobatidae/
OR exp chimpanzee/OR exp gorilla/OR exp orang utan/OR (animal OR
animals OR pisces OR fish OR fishes OR catfish OR catfishes OR sheatfish
OR silurus OR arius OR heteropneustes OR clarias OR gariepinus OR fat-
head minnow OR fathead minnows OR pimephales OR promelas OR cich-
lidae OR trout OR trouts OR char OR chars OR salvelinus OR salmo OR
oncorhynchus OR guppy OR guppies OR millionfish OR poecilia OR gold-
fish OR goldfishes OR carassius OR auratus OR mullet OR mullets OR
mugil OR curema OR shark OR sharks OR cod OR cods OR gadus ORmor-
hua OR carp OR carps OR cyprinus OR carpio OR killifish OR eel OR eels
OR anguilla OR zander OR sander OR lucioperca OR stizostedion OR tur-
bot OR turbots OR psetta OR flatfish OR flatfishes OR plaice OR pleu-
ronectes OR platessa OR tilapia OR tilapias OR oreochromis OR
sarotherodon OR common sole OR dover sole OR solea OR zebrafish OR
zebrafishes OR danio OR rerio OR seabass OR dicentrarchus OR labrax
OR morone OR lamprey OR lampreys OR petromyzon OR pumpkinseed
OR pumpkinseeds OR lepomis OR gibbosus OR herring OR clupea OR
harengus OR amphibia OR amphibian OR amphibians OR anura OR salien-
tia OR frog OR frogs OR rana OR toad OR toads OR bufo OR xenopus OR
laevis OR bombina OR epidalea OR calamita OR salamander OR salaman-
ders OR newt OR newts OR triturus OR reptilia OR reptile OR reptiles OR
bearded dragon OR pogona OR vitticeps OR iguana OR iguanas OR lizard
OR lizards OR anguis fragilis OR turtle OR turtles OR snakes OR snake
OR aves OR bird OR birds OR quail OR quails OR coturnix OR bobwhite
OR colinus OR virginianus OR poultry OR poultries OR fowl OR fowls
OR chicken OR chickens OR gallus OR zebra finch OR taeniopygia OR
guttata OR canary OR canaries OR serinus OR canaria OR parakeet OR
parakeets OR grasskeet OR parrot OR parrots OR psittacine OR psittacines
OR shelduck OR tadorna OR goose OR geese OR branta OR leucopsis OR
woodlark OR lullula OR flycatcher OR ficedula OR hypoleuca OR dove
OR doves OR geopelia OR cuneata OR duck OR ducks OR greylag OR
graylag OR anser OR harrier OR circus pygargus OR red knot OR great
knot OR calidris OR canutus OR godwit OR limosa OR lapponica OR
meleagris OR gallopavo OR jackdaw OR corvus ORmonedula OR ruff OR
philomachus OR pugnax OR lapwing OR peewit OR plover OR vanellus
OR swan OR cygnus OR columbianus OR bewickii OR gull OR chroico-
cephalus OR ridibundus OR albifrons OR great tit OR parus OR aythya OR
fuligula OR streptopelia OR risoria OR spoonbill OR platalea OR leucoro-
dia OR blackbird OR turdus OR merula OR blue tit OR cyanistes OR
pigeon OR pigeons OR columba OR pintail OR anas OR starling OR stur-
nus OR owl OR athene noctua OR pochard OR ferina OR cockatiel OR
nymphicus OR hollandicus OR skylark OR alauda OR tern OR sterna OR
teal OR crecca OR oystercatcher OR haematopus OR ostralegus OR shrew
OR shrews OR sorex OR araneus OR crocidura OR russula OR european
mole OR talpa OR chiroptera OR bat OR bats OR eptesicus OR serotinus
OR myotis OR dasycneme OR daubentonii OR pipistrelle OR pipistrellus
OR cat OR cats OR felis OR catus OR feline OR dog OR dogs OR canis OR
canine OR canines OR otter OR otters OR lutra OR badger OR badgers OR
meles OR fitchew OR fitch OR foumart or foulmart OR ferrets OR ferret
OR polecat OR polecats OR mustela OR putorius OR weasel OR weasels
OR fox OR foxes OR vulpes OR common seal OR phoca OR vitulina OR
grey seal OR halichoerus OR horse OR horses OR equus OR equine OR
equidae OR donkey OR donkeys OR mule OR mules OR pig OR pigs OR
swine OR swines OR hog OR hogs OR boar OR boars OR porcine OR pig-
let OR piglets OR sus OR scrofa OR llama OR llamas OR lama OR glama
OR deer OR deers OR cervus OR elaphus OR cow OR cows OR bos taurus
OR bos indicus OR bovine OR bull OR bulls OR cattle OR bison OR bisons
OR sheep OR sheeps OR ovis aries OR ovine OR lamb OR lambs OR mou-
flon OR mouflons OR goat OR goats OR capra OR caprine OR chamois
OR rupicapra OR leporidae OR lagomorpha OR lagomorph OR rabbit OR
rabbits OR oryctolagus OR cuniculus OR laprine OR hares OR lepus OR
rodentia OR rodent OR rodents OR murinae OR mouse OR mice OR mus
OR musculus OR murine OR woodmouse OR apodemus OR rat OR rats
OR rattus OR norvegicus OR guinea pig OR guinea pigs OR cavia OR por-
cellus OR hamster OR hamsters OR mesocricetus OR cricetulus OR crice-
tus OR gerbil OR gerbils OR jird OR jirds OR meriones OR unguiculatus
OR jerboa OR jerboas OR jaculus OR chinchilla OR chinchillas OR beaver
OR beavers OR castor fiber OR castor canadensis OR sciuridae OR squirrel
OR squirrels OR sciurus OR chipmunk OR chipmunks OR marmot OR
marmots OR marmota OR suslik OR susliks OR spermophilus OR cyno-
mys OR cottonrat OR cottonrats OR sigmodon OR vole OR voles OR
microtus OR myodes OR glareolus OR primate OR primates OR prosimian
OR prosimians OR lemur OR lemurs OR lemuridae OR loris OR bush baby
OR bush babies OR bushbaby OR bushbabies OR galago OR galagos OR
anthropoidea OR anthropoids OR simian OR simians ORmonkey ORmon-
keys OR marmoset OR marmosets OR callithrix OR cebuella OR tamarin
OR tamarins OR saguinus OR leontopithecus OR squirrel monkey OR
squirrel monkeys OR saimiri OR night monkey OR night monkeys OR owl
monkey OR owl monkeys OR douroucoulis OR aotus OR spider monkey
OR spider monkeys OR ateles OR baboon OR baboons OR papio OR rhe-
sus monkey OR macaque OR macaca OR mulatta OR cynomolgus OR fas-
cicularis OR green monkey OR green monkeys OR chlorocebus OR vervet
OR vervets OR pygerythrus OR hominoidea OR ape OR apes OR hylobati-
dae OR gibbon OR gibbons OR siamang OR siamangs OR nomascus OR
symphalangus OR hominidae OR orangutan OR orangutans OR pongo OR
chimpanzee OR chimpanzees OR pan troglodytes OR bonobo OR bonobos
OR pan paniscus OR gorilla OR gorillas OR troglodytes).
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